CSIMarket Company Name, Ticker, Industry, else..
 
Argenx Se  (NASDAQ: ARGX)
 
Price: $1,031.6600 $8.45 0.826%
Day's High: $1039.3599853515625 Week Perf: 1.19 %
Day's Low: $ 1,005.80 30 Day Perf: 20.83 %
Volume (M): 227,987 52 Wk High: $ 1,061.57
Volume (M$): $ 0 52 Wk Avg: $830.96
Open: $1,010.78 52 Wk Low: $661.85



 Market Capitalization (Millions $) 68,120
 Shares Outstanding (Millions) 66
 Employees 1,148
 Revenues (TTM) (Millions $) 8,399
 Net Income (TTM) (Millions $) 1,292
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Argenx is a biopharmaceutical company that focuses on the discovery and development of antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company utilizes its proprietary antibody discovery platforms to identify and develop unique therapeutic candidates. Argenx's lead product, efgartigimod (ARGX-113), is being developed for various autoimmune diseases, including myasthenia gravis and immune thrombocytopenia. The company also has a pipeline of other investigational drugs targeting various indications. Argenx operates globally and collaborates with other pharmaceutical companies to accelerate the development and commercialization of its therapies.


   Company Address: Laarderhoogtweg 25 Amsterdam 1101
   Company Phone Number: 10 70 38 441   Stock Exchange / Ticker: NASDAQ ARGX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -3.15%    
BIIB   -0.67%    
EXEL        0.16% 
GILD   -0.27%    
GLUE        1.2% 
IOVA        1.36% 
• View Complete Report
   



Stocks on the Move

Navigating Market Currents Argenx SEs Strategic Growth Amidst Trading Signals

Published Wed, Aug 21 2024 10:56 AM UTC

In a month marked by dynamic market fluctuations, health care investors and industry stakeholders are closely monitoring leading biopharmaceutical companies like Argenx SE. As we delve into the latest financial and operational highlights, it becomes evident that the trajectory of Argenx SE which specializes in immunology treatments is being shaped by both strategic initiativ...
Stocks on the Move

Argenx SE An Overview of Recent Analyst Sentiments and Promising Developments in the Healthcare Sector

Published Fri, Jul 12 2024 11:39 AM UTC

In recent news, two analysts have expressed their bullish sentiments towards Arcus Biosciences (RCUS) and Argenx SE (ARGX). This article aims to delve into the various news updates surrounding Argenx SE, an emerging genetic medicine company, and explore the recent market trends and developments in the healthcare sector. Additionally, we will provide an overview of Argenx SE ...
Stocks on the Move

J&J Poses a Strong Challenge to Argenxs Vyvgart with Positive Phase III Data

Published Tue, Jul 2 2024 4:30 PM UTC

In recent news, Johnson & Johnson (J&J) has emerged as a formidable competitor to Argenx s Vyvgart with promising results from its Phase III clinical trial for nipocalimab. The data showcases the antibody s effectiveness in improving symptoms associated with myasthenia gravis, a chronic autoimmune neuromuscular disease. J&J s decision to target a broader patient population c...
Stocks on the Move

Argenx Se Expands Autoimmune Pipeline and Achieves FDA Approval for Vyvgart Hytrulo for CIDP

Published Thu, Jun 27 2024 12:27 PM UTC

In the field of immunology, Argenx SE has been making significant strides in addressing severe autoimmune diseases. This article highlights recent developments in Argenx s multifocal motor neuropathy data presentation, the surge in stock prices, and the FDA s approval of Vyvgart Hytrulo for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). These adva...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 8.11
Price to Sales (Expected) -
Price to Book 9.3
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.76
Working Capital Ratio 4.3
Leverage Ratio (MRQ) 0.19
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) 127.21 $
Cash Flow (TTM) -
Cash 52.87 $
Book Value 110.91 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 7,316,521
Net Income per Employee (TTM) 1,125,466
Receivable Turnover Ratio (TTM) 12.84
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 1.01

Profitability Ratios Current
Gross Margin (MRQ) 94.63 %
Operating Margin (MRQ) 12.55 %
Net Margin (MRQ) 15.38 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 15.56 %
Return On Investment (TTM) 18.26 %
Return On Equity (TTM) 18.41 %
Dividend Yield -
Pay out Ratio (TTM) -



Argenx Se's Segments
United States    42.07 % of total Revenue
Japan    2.46 % of total Revenue
China    0.81 % of total Revenue
Rest of the World    4.08 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.